Harness Therapeutics Ltd. has raised fresh financing to further develop its technology for upregulating the translation of ...

Argus raised the firm’s price target on Huntington Bancshares (HBAN) to $19 from $17 and keeps a Buy rating on the shares following the Q4 ...

Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ...

Truist Securities updated its outlook on Huntington Bancshares (NASDAQ:HBAN), increasing the price target from $19.00 to $21.00 while retaining a Buy rating on the stock. The revision reflects the ...